Investor Presentaiton
Long-term
Outlook
Short-term
20
2,47
China Life Sciences - 2022
Limited supply and strong demand will
put upward pressure on the rents of
projects with EIA licenses.
Domestic businesses are expected to
dominate the market, though MNCs will
continue investing and establishing HQs,
innovation and R&D centres.
LSRE investors are expected to become
more active, searching for higher yields
and bridging the supply shortfall
through asset renovation.
An influx of venture capital and top
talent will continue to foster industry
growth. Closer cooperation between
pharmaceutical firms and real estate
companies in project renovation and
operation will be likely.
Regulation and government price
setting will result in industry
consolidation; increasing M&As and
collaborations will generate more office
or lab space demand.
Clusters of businesses, talent and capital
will become more entrenched in key
locations.View entire presentation